Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Kidney transplantation is the preferred treatment for end-stage renal disease, with tacrolimus as a key immunosuppressive agent. Its narrow therapeutic window and variable metabolism necessitate careful monitoring. Genetic polymorphisms in CYP3A5 significantly influence tacrolimus clearance. Expressers (CYP3A5 1 carriers) require higher doses, while non-expressers (*3/3) may be prone to toxicity at standard doses. Although this relationship is well-documented globally, limited data exist from Central India. This retrospective study investigates the impact of CYP3A5 expression on tacrolimus dosing, drug levels, and clinical outcomes in renal transplant recipients to guide personalized immunosuppression in this population.
This retrospective study was conducted at a tertiary care center in Central India on 100 renal transplant recipients. Data collected included demographics, medical history, CYP3A5 polymorphism, post-transplant investigations, graft biopsy results, comorbidities, infections, and new onset diabetes after transplantation (NODAT). Tacrolimus was initiated at 0.1 mg/kg/day for expressors and 0.05 mg/kg/day for non-expressors, with dose adjustments to maintain target C₀ levels. Patients were followed up regularly for one year, with glomerular filtration rate (GFR), serum creatinine, and the concentration/dose (C/D) ratio assessed. One patient who was homozygous for *CYP3A5*3/3 died in the early post-transplant period and was excluded from longitudinal analysis. A p-value ≤ 0.05 was considered statistically significant.
The study stratified renal transplant recipients into expressors (CYP3A51 carriers, n = 38) and non-expressors (CYP3A53/*3, n = 62). One non-expressor patient died within the first post-transplant month due to early graft dysfunction and sepsis; this case was excluded from 1-year follow-up analysis but included in baseline demographic assessment.
Both groups had similar gender distribution, age, and comorbidities, with no significant differences in diabetes, hypertension, or donor type. Tacrolimus dosing was comparable except at 6 and 12 months, where expressors required higher doses. Tacrolimus trough levels were significantly higher in expressors at multiple time points. Kidney function (creatinine and eGFR) showed no significant differences between groups over 12 months. Rates of NODAT, hypomagnesemia, and infections were similar. Biopsy-proven acute rejection was higher in expressors (22.9% vs. 13.1%, P = 0.234). Non-expressors had a significantly higher tacrolimus concentration/dose ratio at multiple follow-ups.
This study shows that CYP3A5 polymorphism affects tacrolimus metabolism, with expressors needing higher doses to maintain therapeutic levels. However, it did not significantly impact graft function or rejection rates, suggesting that TDM helps mitigate its clinical effects.
